Elaprase for intravenous (IV) infusion
SHP-ELA-401
Approved small_molecule completed
Quick answer
Elaprase for intravenous (IV) infusion for Hunter Syndrome is a Approved program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Hunter Syndrome
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed